Personalis is no longer a standalone minimal residual disease story. On July 20 Tempus AI signed an agreement to absorb the Fremont cancer-genomics lab into its precision-oncology platform, and every subsequent print now answers a contract question rather than a franchise question. Holders are slated to receive Tempus Class A paper sized to a $16 headline, with Tempus free to swap as much as half of that paper into cash at the same figure. The ratio floats so the package does not rise if Tempus rallies, and it locks if Tempus sags, which means Personalis shareholders sold a ceiling and kept the acquirer's downside until a narrow walk-right opens. The clinical assay is inflecting in volume and coverage at the same moment the equity stopped compounding that inflection for public holders.
The second-quarter operating picture explains why the board took the bid. Clinical test counts nearly tripled and Medicare now covers four indications, yet first-half revenue was unchanged because one related-party pharma account supplied the entire year-on-year lift. The Tempus commercial channel that books those clinical tests still costs more in order and promotional fees than the clinical line produces. Gross profit did not rise even as the top line did, and operating cash use in the first half ran well ahead of a year earlier against a cash-and-investments pile that funds roughly two years of the current pace. That is a real residual-disease asset trapped inside a lab that has not yet shown it can finance its own reimbursement ramp.
The market has closed most of the earlier discount to the contract. Personalis last changed hands near $16, essentially on top of the stated package, after Tempus itself ripped into the high seventies and left the $48 floor far behind. At that Tempus level the cap binds and the walk-right is dormant, so the remaining debate is no longer what the assay is worth as a public compounder but whether the vote, the antitrust clock, and the April outside date deliver the package or send holders back to a cash-consuming standalone. A stock sitting on the contractual ceiling does not still compensate for selling an inflecting assay unless close is nearly certain.